AcquisitionOther
BIOMARIN PHARMACEUTICAL INC acquired Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
BIOMARIN PHARMACEUTICAL INC -> Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy · $275 million
“ALE1 is a strong strategic fit for BioMarin, bringing a potential oral alternative to the injectable therapies available today for people living with HPP around the world while meaningfully strengthening our early-stage clinical pipeline,” said Alexander Hard
Open source record (SEC) ↗